Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Ultragenyx Pharmaceutical Inc. Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and...
J.P
2025-01-06 | J.P. Morgan Asset Management Strengthens Retirement Business with Strategic Hires | NYSE:JPM
Experienced Retirement Experts Josh Forstater and Tina Anstett Join the FirmNEW YORK, Jan. 6, 2025 /PRNewswire/ -- J.P. Morgan Asset...
